Global Multiple Sclerosis Market Research and Forecast 2018-2023

Posted by Orion Market Research on August 1st, 2018

The Multiple Sclerosis market is projected to witness a steady growth rate of around xx% during the forecasted period 2018-2023. Rising prevalence of multiple sclerosis & awareness program by govt, reimbursement policies are the driving factor of the multiple sclerosis market. According to the National Multiple Sclerosis Society (US), more than 2.3 million peoples living with the multiple sclerosis in the world. The government program for the multiple sclerosis specifically by US government such as emergency assistant program, Assistive technology program and computer program by MS Focus foundation for multiple sclerosis, played the vital role in the growth of the market. High cost of the MS drugs and diagnostics technologies, harmful effects of the treatment and lack of awareness in the emerging economies are restraining the growth of multiple sclerosis market. The robust range of upcoming pipeline drugs for the treatment is the opportunity of the market.

Related Reports: Healthcare Industry Research

Global Multiple Sclerosis market can be bifurcated geographically into North America, Europe, Asia Pacific and Rest of the World. Amongst them, North America and Europe held the largest market share in the global market owing to the growing focus towards awareness of multiple sclerosis. High prevalence of multiple sclerosis in the U.S. has further boosted the growth of the multiple sclerosis market in North America. In 2017, approx. 1 million people living in the multiple sclerosis in the US according to the National Multiple Sclerosis Society. The rapidly developing economies of Asia Pacific are projected to witness the highest growth rate during the forecasted period. The growth in the APAC market is backed by the growing awareness about the diagnosis and treatment options for multiple sclerosis issues coupled with the rising prevalence of neurological disorders within the regional countries. Along with it, efforts by government to increase the awareness about multiple sclerosis and funding programs by the government is helping in the growth of the Asia Pacific Multiple Sclerosis market. The report includes detailed market overview, market determinants, company profiling, sector analysis, market segmentation, geographical analysis, patent analysis, strategic recommendations, key company analysis, gap analysis, key findings, market estimations, market insights, analyst insights and predictive analysis of the market.

Browse full report at: Global Multiple Sclerosis Market Research

The key players of the Multiple Sclerosis market include Abbvie Inc., Bayer AG, Biogen IDEC, Merck KGaA, Novartis, Pfizer In., F.Hoffmann-La-Roche. Product launch, merger & acquisition and partnerships are some of the key strategies adopted by the market players and sustain and capture the major market share in the multiple sclerosis market. On NOV 2017, Roche’s OCREVUS (ocrelizumab) approved by the FDA for relapsing and primary progressive forms of multiple sclerosis. This type approval from FDA is projected to strengthen Roche’s leadership in global multiple sclerosis market.

Research Methodology:

The market study of Multiple Sclerosis Market is incorporated by extensive primary and secondary research conducted by research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.